iThera Medical, a spin-off from the Helmholtz Zentrum München, has closed series C financing with new investors FLUXUNIT, the corporate venture capital arm of OSRAM, and the Wachstumsfonds Bayern. The current investors BayBG and Extorel co-invested in the round. The company will use the funds of over EUR 7 million to accelerate and expand the clinical development of its breakthrough imaging technology, MSOT (multispectral optoacoustic tomography). The initial focus will be on validating its potential in diagnosing inflammatory bowel disease.
MSOT allows optical contrast to be visualized at depths of several centimetres without harming the tissue. The technology has successfully been commercialized for preclinical and clinical research, with over 75 systems currently operational around the world. Now, iThera plans to bring it directly to the patient. Several collaborative studies with universities and university hospitals suggest that MSOT has strong potential to improve diagnosis in a broad range of diseases, enabling earlier and more precise treatment. Highly encouraging results have recently been published in a number of peer-reviewed scientific journals.
Further information:
See iThera's website
